ReviewExpert opinion on investigational drugs2011
Investigational A₃ adenosine receptor targeting agents.
Review in Expert opinion on investigational drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical Translation.Biomolecules · 2026Review
- Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.Molecular neurobiology · 2026Review
- Local delivery of an adenosine receptor agonist reduces inflammation associated with contact hypersensitivity.Drug delivery and translational research · 2025Article
- Genetic and functional modulation by agonist MRS5698 and allosteric enhancer LUF6000 at the native APurinergic signalling · 2024Article
- Adenosine AInternational journal of molecular sciences · 2024Review
- Therapeutic Potential of Highly Selective AMolecules (Basel, Switzerland) · 2022Review
- Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.Advanced drug delivery reviews · 2021Review
- AFrontiers in neuroscience · 2021Review
- AInternational journal of molecular sciences · 2020Review
- Targeting of G-protein coupled receptors in sepsis.Pharmacology & therapeutics · 2020Review
- A binding kinetics study of human adenosine ABiochemical pharmacology · 2018Article
- AMedicinal research reviews · 2018Review
- Anti-inflammatory effect of a novel locally acting APurinergic signalling · 2018Article
- Structure-Affinity Relationships and Structure-Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine AJournal of medicinal chemistry · 2017Article
- Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.Purinergic signalling · 2015Article
- Pharmacological and therapeutic effects of A3 adenosine receptor agonists.Drug discovery today · 2012Review
- Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape.Journal of biomedicine & biotechnology · 2012Review
- Synthesis of purine modified 2'-C-methyl nucleosides as potential anti-HCV agents.Bioorganic & medicinal chemistry letters · 2011Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
introductionAdenosine is an endogenous nucleoside that accumulates in the extracellular space in response to metabolic stress and cell damage. Extracellular adenosine is a signaling molecule that signals by activating four GPCRs: the A(1), A(2A), A(2B) and A(3) receptors. Since the discovery of A(3) adenosine receptors, accumulating evidence has identified these receptors as potential targets for therapeutic intervention. AREAS COVERED: A(3) adenosine receptors are expressed on the surface of most immune cell types, including neutrophils, macrophages, dendritic cells, lymphocytes and mast cells. A(3) adenosine receptor activation on immune cells governs a broad array of immune cell functions, which include cytokine production, degranulation, chemotaxis, cytotoxicity, apoptosis and proliferation. In accordance with their multitudinous immunoregulatory actions, targeting A(3) adenosine receptors has been shown to impact the course of a wide spectrum of immune-related diseases, such as asthma, rheumatoid arthritis, cancer, ischemia and inflammatory disorders. EXPERT OPINION: Given the existence of both preclinical and early clinical data supporting the utility of A(3) adenosine receptor ligands in treating immune-related diseases, further development of A(3) adenosine receptor ligands is anticipated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.